Design Phase Underway for Studies to be Conducted by National Research Council and Lexaria Kelowna, BC /

Design Phase Underway for Studies to be Conducted by National

Research Council and Lexaria

Kelowna, BC / March 14, 2017 / Lexaria Bioscience Corp.

(OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) announces that the formal

design phase for studies to be conducted under the master collaborative research

agreement between the National Research Council of Canada ( NRC ) and Lexaria

A number of studies have been proposed and are currently being

evaluated , with the intention to begin work and produce results over multiple

intervals in the coming months

The studies will be specifically designed to

evaluate and determine the best methods for introducing heat; optimal

temperatures attained; duration of heat and air exposure; and other criteria for

processing lipophilic active agents within foods. Each of cannabinoids (such as

THC), vitamins, NSAIDs and nicotine will be studied. Analytical testing

including chromatography and physicochemical evaluations shall be undertaken, as

required, for thorough analyses.

As well, studies have been proposed to evaluate the chemical

conjugation between the lipophilic active agents and the bioavailability

enhancing agents manipulated by Lexaria s processing methods using analytical

techniques such as nuclear magnetic resonance and/or mass spectrometry to

thoroughly evaluate the nature of any molecular association between the agents

achieved by Lexaria s technology. Results from this study could provide Lexaria

with a chemical or physical fingerprint that can help to identify Lexaria s

technology at work in consumer products, and will certainly lead to a greater

understanding of the results of its processes. Additional studies not noted

herein are also being considered.

In aggregate, results from these studies will add to the

understanding of the physical and biochemical characteristics imparted on

molecules that have been subjected to Lexaria s technology, with a view to

further demonstrating the power of the technology to prospective commercial

partners across the various consumer product sectors the Company is

The results from these studies are expected to greatly assist

the Company in achieving industry partnerships in sectors where the Company is

not currently active. In addition, this work also provides for possible

licensing of any arising, non-competing Lexaria intellectual property to NRC or

its sub-licensees on terms to be defined in the future as applicable.

Lexaria expects that all the studies described herein can be

performed under the master collaboration agreement already entered between the

parties, although feasibility and budgetary evaluations are still under consideration and could

affect our ability to have all these studies completed as expected. Additional

information will be released once the initial study has commenced.

Lexaria Bioscience Corp. is a food

biosciences company with a proprietary technology for improved delivery of

bioactive compounds. The Company s lipophilic enhancement technology has been

shown to enhance the bioavailability of orally ingested cannabinoids, while also

improving taste. This technology promotes healthy ingestion methods, lower

overall dosing and higher effectiveness in active molecule delivery. The

Company s technology is patent-protected for cannabidiol (CBD) and all other

non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol

(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs

(NSAIDs), nicotine and other molecules.

FORWARD-LOOKING STATEMENTS

This release includes

forward-looking statements. Statements which are not historical facts are

forward-looking statements. The Company makes forward-looking public statements

concerning its expected future financial position, results of operations, cash

flows, financing plans, business strategy, products and services, competitive

positions, growth opportunities, plans and objectives of management for future

operations, including statements that include words such as "anticipate," "if,"

"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"

"will," and other similar expressions are forward-looking statements, including

but not limited to: that any additional stock warrants or stock options will be

exercised. Such forward-looking statements are estimates reflecting the

Company's best judgment based upon current information and involve a number of

risks and uncertainties, and there can be no assurance that other factors will

not affect the accuracy of such forward-looking statements. Access to capital,

or lack thereof, is a major risk and there is no assurance that the Company will

be able to raise required working capital. Factors which could cause actual

results to differ materially from those estimated by the Company include, but

are not limited to, government regulation, managing and maintaining growth, the

effect of adverse publicity, litigation, competition, the patent application and

approval process and other factors which may be identified from time to time in

the Company's public announcements and filings. There is no assurance that

existing capital is sufficient for the Company's needs or that it will be able

to raise additional capital. There is no assurance that Lexaria will

successfully complete any other contemplated or existing technology license

agreements; that the expected studies will be carried out with NRC as expected;

or that results from any studies will be favorable or in any way support future

business activities of any kind. There is no assurance that any planned

corporate activity, business venture, or initiative will be pursued, or if

pursued, will be successful. There is no assurance that any of Lexaria s

postulated uses, benefits, or advantages for the patented and patent-pending

technology will in fact be realized in any manner or in any part. No statement

herein has been evaluated by the Food and Drug Administration (FDA). Lexaria

Energy Foods and ViPovaTM products are not intended to diagnose,

treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility

for the adequacy or accuracy of this release.